May 2001 Entelos, Inc. have entered into a research collaboration in rheumatoid arthritis with Organon. In particular, we expect that this collaboration will advance our efforts in target discovery and lead optimisation. Building on the foundations of our proprietary PhysioLab technology and our integrated expertise in immunology, we will develop a PhysioLab biosimulation system for rheumatoid arthritis and use the virtual research environment of the PhysioLab to rapidly simulate experiments in a computer that could take months or years to do in the laboratory or clinic. Using the PhysioLab, researchers can identify novel pathways, validate and prioritise targets and candidates, optimise experiments and clinical trials, understand variable patient outcomes, and thereby increase productivity throughout the drug development pipeline.
Organon is a renowned global pharmaceutical company with a strong commitment to health care.
The company develops and produces innovative prescription medicines for gynaecology, psychiatry, cardiovascular disease and immunology. Entelos, Inc. patented PhysioLab technology provides a breakthrough platform for testing experiments and hypotheses in silico, predicting the results through simulation, and creating knowledge out of fragmented discovery and clinical data. Entelos provides integrated expertise in the metabolic, immunologic, and respiratory areas, and currently offers PhysioLab systems for asthma, obesity, and adipocytes. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users .